Phase 3 Readout
XFOR: Phase 3 Topline: A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positiv
December 30, 2026 · sph4336. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 30, 2026
- Company
- X4 Pharmaceuticals, Inc (XFOR)
- Drug
- sph4336
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positiv
- Drug
- sph4336
- Indication
- Locally Advanced or Metastatic Breast Cancer